eyonis® LCS
Overview
Median Technologies is a pioneer in applying artificial intelligence technologies to medical imaging, developing and marketing eyonis®, a suite of AI-powered Software as a Medical Device (SaMD) for the early diagnosis of solid tumor cancers. eyonis® LCS is specifically designed for lung cancer screening procedures. The company’s mission is to shift the imaging diagnostic paradigm by designing innovative AI/ML tech-based SaMDs, supporting radiologists and healthcare professionals worldwide in screening, early diagnosis, and treatment of cancer. Their vision is to establish eyonis® as a Standard-of-Care (SoC) to reduce the cancer burden by helping identify disease at the earliest stage, allowing better care while avoiding unnecessary medical procedures and reducing healthcare costs. Median Technologies also provides central imaging services and AI-based image analysis for oncology clinical trials in the biopharmaceutical industry through its iCRO business.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI/ML-powered computer-aided detection and diagnosis (CADe/CADx)
- Early detection, localization & diagnosis of solid & part solid pulmonary parenchymal nodules (4-30 mm Longest Average Diameter) on Chest Low-Dose Computed Tomography (LDCT) images.
- Generates DICOM file result reports, PACS available & compatible with every radiologist's viewer.
- Lists all probably benign, suspicious, very suspicious lung nodules present in LDCT image series.
- Scores nodules individually by giving a malignancy score & providing a Likelihood of Malignancy (LOM%) from 1% to 93%.
- 93.3% sensitivity in detecting cancer cases.
- 92.4% specificity in identifying benign cases.
- 99.9% Negative Predictive Value (NPV).
- 66% False Negative reduction.
- 68% False Positive reduction.
Use Cases
- Lung cancer screening programs.
- Aiding radiologists in detecting and characterizing parenchymal pulmonary nodules.
- Supporting clinical decision-making and patient follow-ups.
- Reducing inter-reader variability in lung cancer screening.
- Improving the efficiency and consistency of lung cancer screening programs.
Details
| Category | Oncology AI |
| Pricing | Unknown |
| Deployment | Cloud-based or institution local hosting. DICOM images are collected via the eyonis® Gateway & sent to the eyonis® Cloud for processing. The final result report is then PACS available. |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pulmonology, Radiology |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate eyonis® LCS
Videos
Product demos, reviews, and walkthroughs for eyonis® LCS.
eyonisu00ae LCS, Bringing New Hope to Lung Cancer Patients
Median Technologies






